TENX Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.
Company profile
Ticker
TENX
Exchange
Website
CEO
Anthony DiTonno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
Corporate docs
IRS number
262593535
TENX stock data
()
News
31 Stocks Moving In Wednesday's Mid-Day Session
23 Jun 21
26 Stocks Moving in Wednesday's Pre-Market Session
23 Jun 21
12 Health Care Stocks Moving In Tuesday's After-Market Session
22 Jun 21
Tenax Therapeutics Set To Join Russell Microcap Index
10 Jun 21
Tenax Therapeutics Q1 EPS $(1.64) Down From $(0.38) YoY
17 May 21
Press releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX
7 Jun 21
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
17 May 21
Thinking about buying stock in Naked Brand, Tenax Therapeutics, Iterum Therapeutics, Palantir Technologies, or Orbcomm?
9 Apr 21
Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial "
9 Apr 21
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
7 Apr 21
Investment data
Securities sold
Number of investors
Calendar
17 May 21
24 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.54M | 3.54M | 3.54M | 3.54M | 3.54M | 3.54M |
| Cash burn (monthly) | 904.48K | 68.49K | (positive/no burn) | (positive/no burn) | 1.07M | 818.58K |
| Cash used (since last report) | 2.52M | 190.87K | n/a | n/a | 2.99M | 2.28M |
| Cash remaining | 1.02M | 3.35M | n/a | n/a | 544.52K | 1.26M |
| Runway (months of cash) | 1.1 | 48.9 | n/a | n/a | 0.5 | 1.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Jun 21 | Michael H. Davidson | Common Stock | Grant | Aquire A | No | No | 0 | 512,000 | 0 | 606,645 |
| 11 Jun 21 | Michael H. Davidson | Series B Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 512 | 0 | 0 |
| 11 Jun 21 | Stuart Rich | Common Stock | Option exercise | Aquire M | No | No | 0 | 3,581,000 | 0 | 4,243,517 |
| 11 Jun 21 | Stuart Rich | Series B Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 3,581 | 0 | 0 |
| 11 Jun 21 | Doogan Declan | Common Stock | Option exercise | Aquire M | No | No | 0 | 3,070,000 | 0 | 3,637,871 |
| 11 Jun 21 | Doogan Declan | Series B Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 3,070 | 0 | 0 |
| 10 Jun 21 | Michael H. Davidson | Stock Option Common Stock | Grant | Aquire A | No | No | 2 | 6,250 | 12.5K | 6,250 |
| 10 Jun 21 | Doogan Declan | Stock Option Common Stock | Grant | Aquire A | No | No | 2 | 6,250 | 12.5K | 6,250 |
| 10 Jun 21 | Mitchum James P. | Stock Option Common Stock | Grant | Aquire A | No | No | 2 | 5,000 | 10K | 5,000 |
| 10 Jun 21 | Proehl Gerald T | Stock Option Common Stock | Grant | Aquire A | No | No | 2 | 5,000 | 10K | 5,000 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
25.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 25 |
| Opened positions | 24 |
| Closed positions | 1 |
| Increased positions | 1 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 7.21M |
| Total shares | 3.8M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Armistice Capital | 2.02M | $3.84M |
| Renaissance Technologies | 747.83K | $1.42M |
| BLK Blackrock | 599.1K | $1.14M |
| Vanguard | 177.89K | $338K |
| Dimensional Fund Advisors | 60.41K | $115K |
| Financial Advisory Service | 58.33K | $111K |
| Geode Capital Management | 52.3K | $99K |
| AMP Ameriprise Financial | 30K | $57K |
| NTRS Northern Trust | 17.02K | $32K |
| Citadel Advisors | 15.96K | $30K |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abdominal, absorbed, addressed, adjunct, advice, affirmative, amino, animal, appetite, ATP, automatically, binding, bioavailability, biological, Breakthrough, call, called, cancer, cardioprotective, cascade, causal, central, characterize, CML, confounded, consideration, contractility, convene, conventional, cytochrome, Davidson, Declan, demand, denied, Deregulation, diarrhea, differentiation, discovered, discovery, distention, diverse, Doogan, Dr, dramatic, earlier, edema, employment, enzyme, explored, external, factor, FC, February, Finnish, fluid, formula, gastric, Gleevec, growth, halt, headache, human, imatinib, Imputed, indemnification, inhibit, inhibiting, inhibitor, innovative, inotropic, intangible, intolerance, invited, kinase, largely, led, leukemia, liver, lock, marketplace, Med, mediated, merge, merged, metabolism, metabolized, mitochondrial, morbidity, mortality, multiple, muscle, myeloid, myelosuppression, nausea, NDA, negotiated, noncancer, Opening, organization, orphan, outpatient, overexpressed, PAH, pathway, PDGF, PDGFRA, perfusion, PH, PHPM, PHPrecisionMed, platelet, play, potassium, power, practicable, Precision, preload, produce, progression, promptly, proposal, proposed, protein, protocol, pyrimidine, qualitatively, rare, rash, recognition, recommend, regression, regularly, remeasured, remeasurement, retention, revolutionized, Rich, satisfaction, Secretary, show, showing, signaling, significantly, size, smooth, solicit, sponsor, sponsored, stabilizing, stimuli, Stuart, subpart, successfully, surgery, surrogate, symptomatic, therapy, tissue, tolerability, tolerated, transition, triple, troponin, tyrosine, vasculature, vasodilatory, vomiting, waiver, withdraw, world
Removed:
acceptable, acting, analyzing, applying, arbitral, attendance, audit, belief, bid, bond, Calculation, certify, chain, civil, clarity, compliance, confidence, consecutive, consume, controversy, correct, coverage, criminal, declaration, delist, delisting, Department, discouraging, disruption, economy, epidemic, evaluating, exceed, exercised, expire, faith, False, federal, fewer, forgiven, good, government, governmental, gradient, harm, health, hearing, inaccurate, industry, ineligible, initially, intend, interpretation, interruption, Linkbase, liquidity, listed, listing, lose, matter, media, minimize, minimum, negatively, notification, objective, operation, precautionary, predict, preemption, presently, publicity, qualification, qualifying, regain, reimburse, rejected, rely, remotely, repay, reputation, request, requested, requirement, requiring, resulted, risk, RV, satisfied, satisfy, sensitizer, situation, supply, suspending, temporarily, tolled, tribunal, violation, work
Financial reports
10-Q
2021 Q1
Quarterly report
17 May 21
10-K/A
2020 FY
Annual report (amended)
16 Apr 21
10-K
2020 FY
Annual report
31 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
Current reports
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 21
8-K
Termination of a Material Definitive Agreement
1 Jun 21
8-K
Departure of Directors or Certain Officers
7 Apr 21
8-K/A
Financial Statements and Exhibits
30 Mar 21
8-K
New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development
2 Mar 21
8-K
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
19 Jan 21
8-K
Regulation FD Disclosure
18 Nov 20
8-K
Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation
15 Oct 20
8-K
Tenax Therapeutics Expands Board of Directors with the Appointment
20 Jul 20
8-K
Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings
8 Jul 20
Registration and prospectus
424B3
Prospectus supplement
1 Oct 20
S-3/A
Shelf registration (amended)
11 Sep 20
S-3
Shelf registration
20 Aug 20
D
$5.17M in options / securities to be acquired, sold $5.17M, 1 investor
22 Jul 20
424B5
Prospectus supplement for primary offering
8 Jul 20
D
$317.17K in options / securities to be acquired, sold $317.17K, 1 investor
26 Mar 20
424B5
Prospectus supplement for primary offering
13 Mar 20
S-8
Registration of securities for employees
30 Aug 19
424B4
Prospectus supplement with pricing info
7 Dec 18
S-1/A
IPO registration (amended)
6 Dec 18
Proxies
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
20 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEF 14A
Definitive proxy
15 Jan 18
PRE 14A
Preliminary proxy
28 Dec 17
DEF 14A
Definitive proxy
27 Apr 17
DEF 14A
Definitive proxy
25 Apr 16
DEF 14A
Definitive proxy
16 Aug 15
Other
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
10 Sep 20
UPLOAD
Letter from SEC
3 Sep 20
EFFECT
Notice of effectiveness
10 Dec 18
EFFECT
Notice of effectiveness
24 May 18
UPLOAD
Letter from SEC
21 May 18
CORRESP
Correspondence with SEC
20 May 18
CORRESP
Correspondence with SEC
5 Mar 15
EFFECT
Notice of effectiveness
5 Mar 15
Ownership
SC 13D
TENAX THERAPEUTICS / Doogan Declan ownership change
22 Jun 21
SC 13D
TENAX THERAPEUTICS / Rich Stuart ownership change
22 Jun 21
4
TENAX THERAPEUTICS / James P. Mitchum ownership change
15 Jun 21
4
TENAX THERAPEUTICS / GERALD T PROEHL ownership change
15 Jun 21
4
TENAX THERAPEUTICS / Stuart Rich ownership change
15 Jun 21
4
TENAX THERAPEUTICS / June Sherie Almenoff ownership change
15 Jun 21
4
TENAX THERAPEUTICS / Declan Doogan ownership change
15 Jun 21
4
TENAX THERAPEUTICS / Michael H. Davidson ownership change
15 Jun 21
3
TENAX THERAPEUTICS / Declan Doogan ownership change
15 Jun 21
3
TENAX THERAPEUTICS / Michael H. Davidson ownership change
15 Jun 21
Patents
APP
Utility
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
17 Jun 21
This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
APP
Utility
Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan
21 Oct 20
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives.
GRANT
Utility
Containing element, structure of reinforced ground, process of making said structure of reinforced ground
28 Sep 20
A containing element to be used in geotechnical applications, including: a facing body made of a cementitious material having an inner face configured for contacting the ground and an outer face opposite to the inner face with respect to the body itself, a monolithic reticular structure made of plastic material having a plurality of first and second elements intersecting each other at respective nodes in order to form meshes.
Reddit threads
Daily Discussion Thread - May 18th, 2021
18 May 21
$TENX curling over 50MA/vwap. $ACY loading zone! $TKAT found bottom. Watch NFTS
9 Apr 21
Watchlist for 4/9/2021
9 Apr 21
$GURE $AFMD - watch these! Manage your risk! Biotechs are doing well watching $GLSI, $CELC $TENX $ACY
9 Apr 21
Morning Update for Friday, 04/09/21
9 Apr 21
Daily Discussion Thread - March 29th, 2021
29 Mar 21
Daily Discussion Thread - March 26th, 2021
26 Mar 21
What 3 stocks would you pick if you had to pick 3 and throw the password away for 10 years?
1 Mar 21
Stocks to Watch 19/01/2021
19 Jan 21
Daily Discussion Thread - November 12th, 2020
12 Nov 20